<p><em>“可药用靶点用于治疗视网膜退化”</em></p>
<p><strong>佛罗里达州棕榈滩花园，2026 年 1 月 23 日（环球新闻通讯社）--</strong> Curative Biotechnology, Inc.（OTC: CUBT）（“Curative” 或 “公司”），是一家开发基于二甲双胍的眼药水用于治疗退行性眼病的公司，今天宣布，加拿大知识产权局（CIPO）已对加拿大专利申请号 3,151,011 发出允许通知，标题为 <strong>“可药用靶点用于治疗视网膜退化。”</strong></p>
<p>Curative 是根据与国家眼科研究所（NEI）签署的专利许可协议，全球独家许可该技术。该发明是在 Dr. Kapil Bharti 及其团队在 NEI 的领导下开发的，识别出一个与视网膜退行性疾病进展相关的新型药理靶点。</p>
<p>“在加拿大的这一允许代表了我们建立全球知识产权组合以支持我们眼科平台的重要一步，” Curative Biotechnology 的董事长兼总裁 Paul Michaels 表示。</p>
<p>该加拿大专利包括 22 项已获允许的权利要求，其中包括针对与基于二甲双胍的配方相关的局部眼用给药方法的权利要求，这与公司的预期给药途径相一致。该专利预计将在未来几个月正式发布。</p>
<p>公司之前已宣布计划将其基于二甲双胍的眼药水项目扩展到特定犬类（K9）视网膜退行性疾病的开发，这些疾病机制与人类视网膜退化观察到的机制密切平行。这代表了一条平行的开发路径，可能增强该平台的整体价值，同时满足兽医眼科的未满足需求。</p>
<p>初步目标适应症包括：</p>
<ul>
<li><strong>进行性视网膜萎缩（PRA）</strong></li>
<li><strong>进行性杆锥细胞病（PRCD）</strong>，一种犬类罕见视网膜疾病</li>
</ul>
<p><strong>未来 Curative Biotechnology 新闻稿和更新</strong></p>
<p>感兴趣的股东和投资者可以通过发送电子邮件至 ir@curativebiotech.com 请求未来新闻稿和公司更新的通知。</p>
<p><strong>关于 Curative Biotechnology, Inc.</strong></p>
<p>Curative Biotechnology, Inc.是一家处于开发阶段的生物医学公司，专注于识别和开发罕见疾病的新型治疗方法。公司正在识别、收购和开发具有疾病修饰作用的治疗药物候选者，重点关注罕见疾病适应症。Curative 目前在退行性眼病、传染病和神经肿瘤学领域维持项目。</p>
<p>公司的主要关注点是其退行性眼病平台，得到了来自国家眼科研究所（NEI）和国家卫生研究院（NIH）的全球独家许可。其初步治疗候选药物是基于二甲双胍的重新配方，旨在治疗中期和晚期年龄相关性黄斑变性（AMD）。计划于 2026 年进行首次人体临床试验，具体取决于监管和运营准备情况，依据与 NEI 的合作研究与开发协议（CRADA）。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。前瞻性声明包括但不限于关于专利发布、开发策略、临床时间表和潜在治疗应用的声明。这些声明基于当前的预期和假设，并受到可能导致实际结果显著不同的风险和不确定性的影响。</p>
<p>这些风险包括但不限于与知识产权保护、监管批准、临床开发、资本获取、对第三方合作伙伴的依赖、市场接受度以及公司执行其商业战略能力相关的不确定性。</p>
<p>鼓励读者查看公司在 OTC 市场提交的披露，以获得更全面的风险因素讨论。除法律要求外，公司没有义务更新前瞻性声明。</p>
<p><strong>联系方式：</strong></p>
<p><strong>Paul Michaels</strong></p>
<p>执行董事长</p>
<p>直接电话：917-492-8855</p>
<p><strong>投资者关系</strong></p>
<p>Curative Biotechnology, Inc. (CUBT)</p>
<p>ir@curativebiotech.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UUTROaU0zTXpjNE1EQTBJelV3TURBM01Ea3lOdz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UUTROaU0zTXpjNE1EQTBJelV3TURBM01Ea3lOdz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png"/></p>

CUBT

CUBTD

<p>Curative Biotechnology, Inc. 宣布，加拿大知识产权局已发出其与治疗视网膜退化相关的新型药理靶点的专利申请的允许通知。该专利支持公司基于二甲双胍的眼药水项目，旨在解决人类和犬类的退行性眼病。该专利包括 22 项允许的权利要求，预计将很快正式颁发。Curative 专注于开发罕见疾病的治疗方法，并计划在 2026 年进行其年龄相关性黄斑变性（AMD）治疗的临床试验</p>

<p><em>“Druggable Target to Treat Retinal Degeneration”</em></p>
<div class="lb-trans"><p><em>“可药用靶点用于治疗视网膜退化”</em></p>
</div><p><strong>Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) --</strong> Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing metformin-based eye drops for the treatment of degenerative eye diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled <strong>“Druggable Target to Treat Retinal Degeneration.”</strong></p>
<div class="lb-trans"><p><strong>佛罗里达州棕榈滩花园，2026 年 1 月 23 日（环球新闻通讯社）--</strong> Curative Biotechnology, Inc.（OTC: CUBT）（“Curative” 或 “公司”），是一家开发基于二甲双胍的眼药水用于治疗退行性眼病的公司，今天宣布，加拿大知识产权局（CIPO）已对加拿大专利申请号 3,151,011 发出允许通知，标题为 <strong>“可药用靶点用于治疗视网膜退化。”</strong></p>
</div><p>Curative is the exclusive worldwide licensee of this technology pursuant to a patent license agreement with the National Eye Institute (NEI), part of the National Institutes of Health (NIH). The invention, developed under the leadership of Dr. Kapil Bharti and his team at the NEI, identifies a novel pharmacological target with potential relevance to the progression of retinal degenerative diseases.</p>
<div class="lb-trans"><p>Curative 是根据与国家眼科研究所（NEI）签署的专利许可协议，全球独家许可该技术。该发明是在 Dr. Kapil Bharti 及其团队在 NEI 的领导下开发的，识别出一个与视网膜退行性疾病进展相关的新型药理靶点。</p>
</div><p>“This allowance in Canada represents an important step in our strategy to build a global intellectual property portfolio supporting our ophthalmology platform,” said Paul Michaels, Chairman and President of Curative Biotechnology.</p>
<div class="lb-trans"><p>“在加拿大的这一允许代表了我们建立全球知识产权组合以支持我们眼科平台的重要一步，” Curative Biotechnology 的董事长兼总裁 Paul Michaels 表示。</p>
</div><p>The Canadian patent includes 22 allowed claims, including claims directed toward topical ocular delivery approaches relevant to metformin-based formulations, which align with the Company’s intended route of administration. The patent is expected to formally issue in the coming months.</p>
<div class="lb-trans"><p>该加拿大专利包括 22 项已获允许的权利要求，其中包括针对与基于二甲双胍的配方相关的局部眼用给药方法的权利要求，这与公司的预期给药途径相一致。该专利预计将在未来几个月正式发布。</p>
</div><p>The Company has previously announced plans to expand development of its metformin-based eye drop program into select canine (K9) retinal degenerative indications, where disease mechanisms closely parallel those observed in human retinal degeneration. This represents a parallel development pathway that may enhance the overall value of the platform while addressing unmet needs in veterinary ophthalmology.</p>
<div class="lb-trans"><p>公司之前已宣布计划将其基于二甲双胍的眼药水项目扩展到特定犬类（K9）视网膜退行性疾病的开发，这些疾病机制与人类视网膜退化观察到的机制密切平行。这代表了一条平行的开发路径，可能增强该平台的整体价值，同时满足兽医眼科的未满足需求。</p>
</div><p>Initial target indications include:</p>
<div class="lb-trans"><p>初步目标适应症包括：</p>
</div><ul>
<li><strong>Progressive Retinal Atrophy (PRA)</strong></li>
<li><strong>Progressive Rod and Cone Disease (PRCD</strong>), a rare retinal disease in canines</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>进行性视网膜萎缩（PRA）</strong></li>
<li><strong>进行性杆锥细胞病（PRCD）</strong>，一种犬类罕见视网膜疾病</li>
</ul>
</div><p><strong>Future Curative Biotechnology Press Releases and Updates</strong></p>
<div class="lb-trans"><p><strong>未来 Curative Biotechnology 新闻稿和更新</strong></p>
</div><p>Interested shareholders and investors may request notification of future press releases and corporate updates by emailing ir@curativebiotech.com.</p>
<div class="lb-trans"><p>感兴趣的股东和投资者可以通过发送电子邮件至 ir@curativebiotech.com 请求未来新闻稿和公司更新的通知。</p>
</div><p><strong>About Curative Biotechnology, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Curative Biotechnology, Inc.</strong></p>
</div><p>Curative Biotechnology, Inc. is a development-stage biomedical company focused on the identification and development of novel therapeutic approaches for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with an emphasis on rare disease indications. Curative currently maintains programs in degenerative eye disease, infectious disease, and neuro-oncology.</p>
<div class="lb-trans"><p>Curative Biotechnology, Inc.是一家处于开发阶段的生物医学公司，专注于识别和开发罕见疾病的新型治疗方法。公司正在识别、收购和开发具有疾病修饰作用的治疗药物候选者，重点关注罕见疾病适应症。Curative 目前在退行性眼病、传染病和神经肿瘤学领域维持项目。</p>
</div><p>The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial therapeutic candidate is a metformin-based reformulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is planned for 2026, subject to regulatory and operational readiness, under a Cooperative Research and Development Agreement (CRADA) with the NEI.</p>
<div class="lb-trans"><p>公司的主要关注点是其退行性眼病平台，得到了来自国家眼科研究所（NEI）和国家卫生研究院（NIH）的全球独家许可。其初步治疗候选药物是基于二甲双胍的重新配方，旨在治疗中期和晚期年龄相关性黄斑变性（AMD）。计划于 2026 年进行首次人体临床试验，具体取决于监管和运营准备情况，依据与 NEI 的合作研究与开发协议（CRADA）。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding patent issuance, development strategies, clinical timelines, and potential therapeutic applications. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。前瞻性声明包括但不限于关于专利发布、开发策略、临床时间表和潜在治疗应用的声明。这些声明基于当前的预期和假设，并受到可能导致实际结果显著不同的风险和不确定性的影响。</p>
</div><p>Such risks include, among others, uncertainties related to intellectual property protection, regulatory approvals, clinical development, access to capital, reliance on third-party collaborators, market acceptance, and the Company’s ability to execute its business strategy.</p>
<div class="lb-trans"><p>这些风险包括但不限于与知识产权保护、监管批准、临床开发、资本获取、对第三方合作伙伴的依赖、市场接受度以及公司执行其商业战略能力相关的不确定性。</p>
</div><p>Readers are encouraged to review the Company’s disclosures filed with OTC Markets for a more complete discussion of risk factors. The Company undertakes no obligation to update forward-looking statements, except as required by law.</p>
<div class="lb-trans"><p>鼓励读者查看公司在 OTC 市场提交的披露，以获得更全面的风险因素讨论。除法律要求外，公司没有义务更新前瞻性声明。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>Paul Michaels</strong></p>
<div class="lb-trans"><p><strong>Paul Michaels</strong></p>
</div><p>Executive Chairman</p>
<div class="lb-trans"><p>执行董事长</p>
</div><p>Direct: 917-492-8855</p>
<div class="lb-trans"><p>直接电话：917-492-8855</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>Curative Biotechnology, Inc. (CUBT)</p>
<div class="lb-trans"><p>Curative Biotechnology, Inc. (CUBT)</p>
</div><p>ir@curativebiotech.com</p>
<div class="lb-trans"><p>ir@curativebiotech.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZek1UUTROaU0zTXpjNE1EQTBJelV3TURBM01Ea3lOdz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYzMTQ4NiM3Mzc4MDA0IzUwMDA3MDkyNw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjI4ZjAwYjQtNTNhZS00NDMzLThkYWMtNmZlNmJmOWZiY2Y2LTUwMDA3MDkyNy0yMDI2LTAxLTIzLWVu/tiny/Curative-Biotechnology-Inc-.png"/></p>

Curative Biotechnology 宣布获得加拿大专利许可 | CUBT 股票新闻